Markets:
DJIA +559.391.68%
NASDAQ +111.690.80%
S&P +55.331.33%
Featured Stocks:
PETS +5.40% 34.13
AN +3.35% 91.74
DKNG +2.21% 49.12
CREE +1.15% 92.09

asco

Article Index

Where the AstraZeneca Stock Price Is Headed After ASCO 2015

By , Associate Editor, Money Morning • @KyleAndersonMM -

Astrazeneca stock price

The AstraZeneca stock price is hovering near $68 after the company presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago this week.

ASCO is an annual event that's attended by 30,000 people and hosts more than 4,000 presentations. This year's meeting began on May 29 and ran through June 2.

Here's everything you need to know about AstraZeneca's presentation at ASCO and the AZN stock price...

Best Stocks to Buy: Cash In on a New $35 Billion Biotech Market

By , Associate Editor, Money Morning • @TaraKateClarke -

biotech

Each week our Money Morning experts dish out the latest profit plays - and asset-protection moves - for our Money Morning Members - all for free.

Last week, Money Morning's best stocks to buy included five biotech picks. Four of them are blazing trails in immuno-oncology. Our fifth biotech pick has already tripled in value in the last six months, and it's not done yet.

Aside from these biotech winners, we covered an ETF play on the European Central Bank's recent policy changes, the best stock in "unified computing," and a smart gold buy at a discount.

Get these plus more of our latest, best stocks to buy.

Investing in Biotech Stocks: Why the "ASCO Effect" Rally Could Start Tomorrow

By , Executive Editor, Money Morning • @privatebrief -

Get ready to profit from the "ASCO Effect."

Each June, the American Society of Clinical Oncology (ASCO) hosts its annual meeting - an event that's attended by 30,000 people and the scene of 4,000 presentations.

And each May, just ahead of this crucial gathering, a select group of oncology stocks takes investors on a pretty wild ride - almost like clockwork.

That's the "ASCO Effect."

The catalyst for this big run-up - in which some stocks double, triple or quadruple in price (or more) - is well-known. A few weeks ahead of the meeting, ASCO posts drug-research abstracts of some of the presenting companies on its Website; investors look at the clinical-trial results contained in the abstracts, and key on the most-promising players - igniting share rallies so torrid that they're remembered for years.

This year's ASCO annual meeting is scheduled for June 1-5 in Chicago.

But, according to the latest reports we've seen, the abstracts are due out at 6 p.m. (EDT) today (Wednesday).

If that deadline is met, you can bet that investors will be scouring those abstracts all night.

If you want an example of the ASCO Effect in action, just look at what happened with OXiGENE Inc. (Nasdaq: OXGN) shares just 12 months ago. As May opened last year, OXiGENE was a relatively unremarkable biotech stock. Indeed, the company was juggling a lot of problems.

OXiGENE faced questions about its management turnover and its cash position. Shareholders were worried about its cancer-drug pipeline. And the stock was trading at less than $2 a share.

In fact, OXiGENE shares had been one of the biotech sector's worst performers in 2010, and the company had to endure the ignominy of a reverse stock split in February 2011.

Then came the ASCO Effect.

To continue reading, please click here...